SCHEMBL5358278

SCHEMBL5358278

Cc1ccsc1C=C1C(=O)Nc2ccc(CO)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.46
S1PR4 O95977 1/20 0.46
HSP90AA1 P07900 1/20 0.46
ALOX12 P18054 1/20 0.46
S1PR1 P21453 1/20 0.46
NTSR1 P30989 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
KDR P35968 3/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 1/20 0.45
PDPK1 O15530 4/20 0.43
LRRK2 Q5S007 1/20 0.43
RET P07949 3/20 0.42
PDGFRB P09619 1/20 0.42
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364110 0.88 PDPK1 (0.56) MEN1KMT2AMAPTALDH1A1S1PR4
SCHEMBL5365601 0.86 MEN1 (0.45) MEN1KMT2AMAPTALDH1A1S1PR4
SCHEMBL6297823 0.81 LRRK2 (0.60) LRRK2RETPDGFRB
SCHEMBL6297819 0.81 LRRK2 (0.60) LRRK2RETPDGFRB
SCHEMBL5364695 0.80 RET (0.44) MEN1KMT2AMAPTALDH1A1KDR
SCHEMBL5359359 0.79 TLK2 (0.47) MEN1KMT2AMAPTALDH1A1KDR
SCHEMBL5362148 0.79 KDR (0.48) ALDH1A1KDRPDPK1RETPDGFRB
SCHEMBL5361719 0.79 PDPK1 (0.58) KDRPDPK1PDGFRB
SCHEMBL5727509 0.78 KDR (0.71) MEN1KMT2AMAPTALDH1A1ALOX12
SCHEMBL5727507 0.78 KDR (0.71) MEN1KMT2AMAPTALDH1A1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MEN1 3855/4885KMT2A 4060/4885MAPT 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.